DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN

NCT06784713 | Completed

• 1 other identifier: 268/T-15
• Study Type: observational
• Target: 127,277
• Locations: 1 country
• Sites: 1

Brief Summary

The study focuses on Estonian children under 18 who had COVID-19 from 27.02.2020 to 01.03.2023. The main aim is to find out the risk factors for severe COVID-19 in children. In order to do that the study includes their demographic data, vaccination status, and details about the severity of illness, such as hospitalization and long-term effects of COVID-19.

Conditions

COVID - 19; Diabetes Mellitus; Post-COVID Conditions; MIS-C Associated With COVID-19

Outcome Measures

Primary Outcomes (5)

• Hospitalization due to COVID-19

  Cases requiring hospital care due to COVID-19, hospitalization length, need for intensive care

  From enrollment to the end of the observation period in Oct 2023

• Post-COVID condition

  Receiving post COVID-19 syndrome (ICD-10 code U09) diagnosis after acute COVID-19 infection, the time from COVID-19 to long-COVID

  From enrollment to the end of the observation period in Oct 2023

• Diabetes mellitus

  Receiving diabetes mellitus (ICD-10 code E10) diagnosis after acute COVID-19 infection

  From enrollment to the end of the observation period in Oct 2023

• MIS-C

  Receiving MIS-C diagnosis (ICD-10 code U10)

  From enrollment to the end of the observation period in Oct 2023

• Mortality

  Cases of COVID-19 that resulted in death

  From enrollment to the end of the observation period in Oct 2023

Study Arms (1)

COVID-19 children and adolescents

All the Estonian children aged \<18 years with SARS-CoV-2 positivity or COVID-19 diagnosis (ICD-10 codes U07.1, U07.2)

Eligibility Criteria

• Age: 0 Days - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

All the Estonian children and adolescents (under 18 yo) who received COVID-19 diagnosis or positive SARS-CoV-2 test in a 3 year period

You may qualify if:

• SARS-CoV-2 positivity or COVID-19 diagnosis (ICD-10 codes U07.1, U07.2)
• COVID-19 diagnosis in the following time period: 27/Feb/2020 to 01/Mar/2023

You may not qualify if:

• age above 18 years

Sponsors & Collaborators

• University of Tartu: lead

Study Sites (1)

University of Tartu

Tartu, Estonia

Location

MeSH Terms

Conditions

COVID-19; Diabetes Mellitus; Post-Acute COVID-19 Syndrome; pediatric multisystem inflammatory disease, COVID-19 related

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Post-Infectious Disorders; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Medical Microbiology

Study Record Dates

• First Submitted: January 17, 2025
• First Posted: January 20, 2025
• Study Start: February 27, 2020
• Primary Completion: March 1, 2023
• Study Completion: October 23, 2023
• Last Updated: January 20, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)